Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective
The low availability of NRAMs in national and provincial medical institutions indicates that their willingness to equip NRAMs needs to be improved. All factors examined in this study affected the availability of NRAMs. Our findings can guide policymakers in improving relevant policies.
Authors
- Zepeng Wang (ORCID: https://orcid.org/0009-0007-8658-1983)
- Wenxin Meng (ORCID: https://orcid.org/0000-0003-1147-0537)
- Jinping Xie
- Rong Jiang (ORCID: https://orcid.org/0009-0008-9305-4978)
- Shudi Yang
Institutions
- China Pharmaceutical University (CN)
Publication Details
- Journal
- BMC Public Health
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1186/s12889-024-19786-y
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China